Table 2.

Pharmacokinetic parameters of mAb1 following IV administration of 10 mg/kg mAb1 to mice (from non-compartmental pharmacokinetic analysis; n = 6–8; mean ± SD).

Parameter	Unit	Cohort 1: Tg32 BM in Tg32 mice	Cohort 2: ko BM in Tg32 mice	Cohort 3: Tg32 BM in ko mice	Cohort 4: ko BM in ko mice*
CL	[mL/day/kg)]	12.9 ± 2.5 a	67.4 ± 18.1 b	98.8 ± 17.0 c	159 ± 24
Vc	[mL/kg]	19.4 ± 3.7	20.1± 5.1	30.9 ± 10.2	50.5 ± 7.5
Vss	[mL/kg]	112 ± 23	78.2 ± 19.9	102 ± 23	103 ± 22
t1/2	[day]	6.8 ± 1.1 a	1.2 ± 0.2 d	1.0 ± 0.3 e	0.62 ± 0.10
AUC(0-inf)	[(µg·h)/mL]	19300 ± 3860	3750 ± 840	2490 ± 425	1530 ± 224
Cmax	[µg/mL]	510 ± 104	437 ± 72	334 ± 111	192 ± 29

^*n = 6; CL: clearance; Vc: central volume of distribution; Vss: volume of distribution at steady state; t1/2: apparent terminal half-life; AUC: area under the plasma concentration-time curve; Cmax: maximum plasma concentration.

Statistical comparisons by one-way ANOVA followed by Tukey's multiple comparison test:

^a p < 0.0001 versus cohorts 2, 3 and 4;

^b p < 0.01 versus cohort 3, p<0.001 versus cohort 4;

^c p < 0.001 versus cohort 4;

^dnon-significant (ns) versus cohort 3, p<0.01 versus cohort 4;

^e p < 0.01 versus cohort 4.